Trading around €40.74, the stock sits comfortably above its 200-day moving average but remains about 17% below its 52-week high of €49.17. The coming months will test whether the market's faith in ...
The drug finerenone, marketed as Kerendia, is central to Bayer's growth strategy. It recently secured a major win as the European Commission approved it for a second indication: treating heart failure ...
4don MSNOpinion
Bayer, MustGrow Biologics, and Yara International: How to capitalize on the 40% fertilizer price surge in your portfolio
Bayer: Between a Crop Offensive and Pharmaceutical Hope Bayer’s Crop Science division is relying on an unusual weapon in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results